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Abstract
Purpose: This study aims to determine the effect of human mesenchymal stem cell (hMSC)
labeling with the fluorescent dye DiD and the iron oxide nanoparticle ferucarbotran on
chondrogenesis.
Procedures: hMSCs were labeled with DiD alone or with DiD and ferucarbotran (DiD/
ferucarbotran). hMSCs underwent confocal microscopy, optical imaging (OI), and magnetic
resonance (MR) imaging. Chondrogenesis was induced by transforming growth factor-b and
confirmed by histopathology and glycosaminoglycan (GAG) production. Data of labeled and
unlabeled hMSCs were compared with a t test.
Results: Cellular uptake of DiD and ferucarbotran was confirmed with confocal microscopy. DiD
labeling caused a significant fluorescence on OI, and ferucarbotran labeling caused a significant
T2* effect on MR images. Compared to nonlabeled controls, progenies of labeled MSCs
exhibited similar chondrocyte morphology after chondrogenic differentiation, but the labeled cells
demonstrated significantly reduced GAG production (pG0.05).
Conclusion: DiD and DiD/ferucarbotran labeling of hMSC does not interfere with cell viability or
morphologic differentiation into chondrocytes, but labeled cells exhibit significantly less GAG
production compared to unlabeled cells.
Key words: Optical imaging, Magnetic resonance imaging, Molecular imaging, Cell labeling,
Mesenchymal stem cell, Superparamagnetic iron oxide, DiD, Differentiation, Contrast agent
Introduction
C
artilage lacks self-regeneration capacity, which makes
regenerating structural damage to articular cartilage a
particularly challenging problem. Stem cell transplants
provide a potentially curative therapeutic option. However,
there are many obstacles related to stem cell-mediated
cartilage regeneration such as (a) achieving successful stem
cell retention at the implantation site, (b) differentiation of
the transplanted stem cells into chondrocytes, and (c)
regeneration of hyaline cartilage instead of fibrous cartilage
[1].
A noninvasive imaging technique for long-term in vivo
detection of transplanted stem cells would significantly
enhance our ability to identify factors that lead to cartilage
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Classical methods to monitor stem cell transplants have
relied on postmortem histopathological analyses, which
would not be clinically applicable. Novel noninvasive
multimodality imaging approaches would be readily clin-
ically applicable and could combine high sensitivity (as
provided by optical imaging techniques) with direct
cartilage depiction (as provided by magnetic resonance
(MR) imaging) for high-resolution stem cell tracking in
real time [2].
In order to track stem cells and/or their progenies in
cartilage defects with a combined OI and MR imaging
approach, the cells have to be labeled with markers that can
be detected with either technique. Exogenous markers have
the advantage of being easy to apply, while not being
associated with genetic modifications of the labeled cells.
However, it has been recently discussed, controversially, if
cellular contrast agent markers may inhibit chondrogenesis
of human mesenchymal stem cells (hMSCs) [3, 4]. Thus, the
purpose of this study was to investigate the effect of hMSC
labeling with the fluorescent dye DiD and the iron oxide
nanoparticle ferucarbotran on chondrogenesis.
Materials and Methods
Cell Culture
After institutional approval and donor consent, primary hMSCs
were aspirated from bone marrow (BM) in the iliac crest of a 20-
year-old male patient with no known bone marrow pathology, who
was admitted to our institution for trauma surgery. BM cells were
plated and incubated for 12 h. Nonadherent cells were removed and
remaining cells were cultured in Dulbecco’sm o d i f i e dE a g l e
medium (DMEM) high glucose media (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS; Hyclone,
Logan, UT, USA) and 1% penicillin–streptomycin at 37°C in a
humidified 5% CO2 atmosphere. The culture media were changed
every third day. The cells were passaged upon reaching 90%
confluency and either redistributed to new culture flasks or used for
experiments. All experiments were performed between passages
8–12 to optimize chondrogenic potential and avoid senescence.
Three groups were investigated: nonlabeled hMSCs [1], hMSCs
labeled with the fluorescent dye DiD [2], and hMSCs labeled with
the MR contrast agent ferucarbotran in addition to the fluorescent
dye DiD (DiD/ferucarbotran) [3].
Cell Labeling Procedure
1. DiD (C67H103CIN2O3S: vibrant cell labeling solution, Molecular Probes,
Eugene, OR, USA) is a lipophilic, carbocyanine near-infrared (NIR)
fluorochrome with a molecular weight of 1,052 DA and excitation/
emission maximum of 644/665 nm. Samples of 1.0×10
6 hMSC were
incubated with 5 µl of DiD in 1 ml of serum-free media for 20 min and
then washed three times with phosphate-buffered saline (PBS) by
sedimentation.
2. Ferucarbotran (Resovist: Bayer Schering AG, Berlin, Germany) consists
of carboxydextran-coated superparamagnetic particles of iron oxides
(SPIOs). Ferucarbotran is characterized by a mean diameter of 60 nm, a
net negative charge, as well as r1 and r2 relaxivities of 25 and 151 mM
−1
s
−1, respectively [5]. Samples of 1.0×10
6 hMSC were incubated with
ferucarbotran (100 μg Fe/ml serum-free high-glucose DMEM) for 2 h.
Then, 10% FBS was added and cells were incubated for an additional
12 h. The cells were carefully washed three times with PBS (pH7.4) by
sedimentation (5 min, 400 rcf, 25°C). The ferucarbotran-labeled cell
pellet was resuspended and labeled with DiD as described above. A
serial dilution was prepared of DiD/ferucarbotran-labeled hMSCs and
nonlabeled controls with decreasing cell numbers for subsequent MR and
OI. Following each labeling procedure, the cells were counted using a
hemocytometer (Neugebauer Chamber), and cell viability was tested by
the trypan blue exclusion assay (Sigma Aldrich, St. Louis, MO, USA).
Representative samples of labeled hMSC and unlabeled controls, prior to
differentiation, were imaged using a Zeiss-LSM 510 confocal micro-
scope (Carl Zeiss MicroImaging, Inc., Thornwood, NY, USA) to confirm
labeling and localization. All hMSC samples were mounted with
Vectashield containing 4′,6-diamidino-2-phenylindole (DAPI; Vector
Laboratories, Burlingame, CA, USA). Ferucarbotran-labeled samples
were also stained with antidextran fluorescein isothiocyanate (FITC;
Stem Cell Technologies, Tukwila, WA, USA) for iron localization.
MRI
In vitro imaging studies of hMSCs and chondrogenic cell pellets
were performed with a 1.5-T MR scanner (Signa EXCITE HD; GE
Medical Systems, Milwaukee, WI, USA). The chondrogenic pellets
were imaged in polypropylene tubes and were immersed in a water
bath (20°C) to diminish susceptibility artifacts. The samples were
scanned with a circularly polarized quadrature knee coil (Clinical
MR Solutions, Brookfield, WI, USA). Axial sequences were
obtained using a T2*-weighted GE sequence (TR 500, multiple
TE 28.8:14.4:7.2:3.7 ms, BW 15.63 Hz, FOV12, matrix 256×196,
NEX 1, alpha 30).
OI
Images of hMSCs and chondrogenic pellets were acquired and
analyzed using Living Image 2.5 software (Xenogen, Alameda,
CA, USA) integrated with Igorpro (Wavemetrics, Lake Oswego,
OR, USA). The optical imager is an integrated fluorescence system
(400–900 nm) that is composed of a light-tight specimen chamber
(dark box) and a 0.5-in. charge-coupled device (CCD) camera. To
minimize electronic background and maximize sensitivity, the CCD
camera is thermoelectrically cooled to −70°C. Prior to acquiring the
fluorescence-based optical images, gray scale images (i.e., a regular
photograph) were acquired using unfiltered light from the excitation
source, which were later fused with fluorescence images using IVIS
software. All in vitro samples underwent OI using Cy5.5 filter
preset (excitation filter passband 615–665 nm, emission filter
passband 695–770 nm, background filter passband 580–610 nm)
to match the absorption and emission characteristics of the labeling
fluorophore, and unfiltered light from the excitation source was
used for the photograph. Specifically, while DiD exhibits its
maximum emission intensity at about 665 nm, the emission
spectrum extends to about 800 nm with about half of the emitted
photon flux at wavelengths longer than 695 nm, which allows them
to be captured by the imaging system using the Cy5.5 filter set.
The IVIS system has implemented a subtraction method to
minimize the effect of residual background signal and autofluor-
escence that may be detected during fluorescent imaging. This
subtraction method is executed by first acquiring an image with
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another image with the background excitation filter. The back-
ground noise can then be subtracted. A detailed description of the
imaging system is provided by Troy et al. [5]. Consistent
illumination parameters were used for all NIR fluorescent
acquisitions. Normalized images are obtained by dividing the
fluorescent image by a reference illumination image, and thus,
images are unitless. The resulting “normalized” image displays
each pixel in the unit of “average efficiency” which represents the
fractional ratio of fluorescent emitted photons per incident
excitation photon (Xenogen, Alameda, CA, USA). For in vitro
image analysis, regions-of-interest were defined as the circular
area of the pellet.
Chondrogenic Differentiation
For each experimental group, four samples of 2.5×10
5 hMSCs (n=4
DiD,n=4 DiD/ferucarbotran,andn=4unlabeledcontrolhMSC)were
suspended in 0.5 ml of complete chondrogenic media (Chondrogenic
DifferentiationBulletkit;LonzaGroupLtd.,Switzerland)preparedper
manufacturer’s protocol (Lonza Group Ltd., Switzerland) containing
10 ng/ml recombinant transforming growth factor (TGF)-β3. The
aliquot was transferred to 15 ml polypropylene culture tubes (VWR,
WestChester,PA,USA)andcentrifugedat150rcffor5mintoforma
pelleted micromass and subsequently incubated at 37°C in a
humidified atmosphere of 5% CO2. The media were changed every
2 days and the culture ended after 14 days.
Glycosaminoglycan Quantification
The absorbant assay, dimethylmethylene blue (DMMB), was used to
assess the total glycosaminoglycan (GAG) content in the differ-
entiation samples [6]. After the 14-day culture, each pellet was
suspended in 0.5 ml 1× TE buffer, and the corresponding cumulative
chondrogenic induction medium was homogenized for comparison to
standard curves of chondroitin sulfate following the addition of
250 µl DMMB solution (21 mg DMMB, 5 ml absolute ethanol, and
2 g sodium formate; pH3.5). Average total GAG content and relative
GAG content were calculated for each triplicate sample.
Histopathologic Evaluation of Chondrogenic
Differentiation
The chondrogenic pellets were removed from test tubes, placed
in 10% neutral buffered formalin, and then encapsulated in
HistoGel (both Richard-Allan Scientific, Kalamazoo, MI, USA).
The specimens were paraffin-embedded, sectioned into 5-µm
transverse slices, and stained with Alcian blue (stains acid
mucopolysaccharides and glycosaminoglycans) and safranin-O
(glycosaminoglycans).
Statistical Analysis
Imaging data and GAG data were displayed as means and standard
deviations (SD). Data of labeled and unlabeled cells were tested for
significant differences with a Student’s t test. Statistical signifi-
cance was assigned for p valuesG0.05.
Results
Cell Labeling Procedure
1. hMSC labeling with DiD: The trypan blue test revealed
a cell viability of 97%±3% before and 96%±3% after
the labeling procedure, which was not significantly
different (p90.05). Confocal microscopy demonstrated
that unlabeled hMSC showed no fluorescence (Fig. 1a)
while there was uptake of DiD within the hMSC
(Fig. 1b).
2. hMSC labeling with DiD/ferucarbotran: The trypan blue
test revealed a cell viability of 96%±3% before and
95%±3% after the labeling procedure, which is not sig-
nificantly different (p90.05). Confocal microscopy demon-
strated the internalization of ferucarbotran in the cytoplasm
of the cell (Fig. 1c).
Fig. 1. High-power (×40) confocal microscopy of a unlabeled control, b DiD-labeled hMSCs, and c DiD/ferucarbotran-labeled
hMSCs stained with antidextran FITC stain. The nuclei of all hMSC have been counterstained with DAPI (blue channel). There
was significant uptake of both contrast agents within the hMSC (b, c).
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1. Unlabeled hMSC did not show a significant fluorescent
signal on OI images and showed a signal similar to
culture medium on T2-weighted MR images immediately
following labeling (Fig. 2a, b).
2. DiD-labeled hMSC showed a significantly stronger
fluorescence with OI compared to unlabeled controls
(pG0.05; Fig. 3a, b). The unlabeled control was used as
the baseline sample and was normalized to zero. A
fluorescent signal remained detectable throughout the
differentiation culture, up to 14 days (Fig. 3b). The mean
total fluorescent intensity of the DiD-labeled hMSCs
(measured in units of efficiency) was 4.51E−07 with a
standard deviation of 2.19E−05. The T2*-signal on MR
images of DiD-labeled hMSC and unlabeled controls was
not significantly different (p90.05; Fig. 3a, b).
3. DiD/ferucarbotran-labeled hMSC also showed a signifi-
cantly stronger fluorescence with OI compared to
unlabeled controls immediately following labeling
(Fig. 2a), and this remained detectable following differ-
entiation for up to 14 days (Fig. 3c). The unlabeled
control was used as the baseline sample and was nor-
malized to zero. The mean total fluorescent intensity of
the DiD/ferucarbotran-labeled hMSC (measured in units
of efficiency) following differentiation was 1.25E−06
with a standard deviation of 6.13E−05. In addition, DiD/
ferucarbotran-labeled cells demonstrated a significantly
decreased T2*-signal compared to unlabeled controls on
MR images (Figs. 2b and 3a, c).
Chondrogenic Differentiation
1. Histologic analysis of the unlabeled cell pellets at 14 days
after TGF-b induced successful differentiation supported
by positive stains for Alcian blue and safranin-O (Fig. 4).
The average total GAG content of the unlabeled control
was 23.31 (SD 6.30; Fig. 5).
2. The DiD-labeled pellet also revealed cells with similar
architecture to that of the control supported by positive
stains for Alcian blue and safranin-O (Fig. 4;T a b l e1).
The average total GAG content of the DiD-labeled
sample was 14.20 (SD 2.33). The relative GAG content
Fig. 3. Optical images (upper row) and MR images (lower
row)o fa, nonlabeled control pellet, b DiD-labeled pellet, and
c DiD/ferucarbotran-labeled pellet. A representative color
scale is provided which displays the fluorescence intensity
above a certain threshold. All labeled pellets demonstrate a
significant fluorescent signal on OI for the given threshold (b,
c). The fluorescence signal is not homogenously distributed
on the optical images due to the fact that the cells were
centrifuged prior to imaging which caused the pellet to stick
to one side. T2*-weighted MR images of DiD/ferucarbotran-
labeled pellets demonstrate a significant decrease in signal
(c). The MR signal seen in the lower row of c shows a
blooming effect compared to the corresponding OI, which is
caused by an extended range susceptibility effect of the
magnetic particles within the cells.
Fig. 2. A serial dilution was prepared of DiD/ferucarbotran-labeled hMSCs and unlabeled controls with decreasing cell
numbers. a OI signal of DiD/ferucarbotran-labeled hMSCs (units in efficiency) and nonlabeled controls showed increased
fluorescent signal with increased cell numbers. b MR images of DiD/ferucarbotran-labeled hMSCs demonstrated a significantly
decreased T2*-signal with increasing cell number.
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control was 0.54 (SD 0.09). Total and relative GAG
production of DiD-labeled hMSC was significantly reduced
compared to unlabeled controls (pG0.05; Fig. 5).
3. DiD/ferucarbotran-labeled samples showed similar chon-
drogenic differentiation to that of the control with positive
stains for Alcian blue and safranin-O (Fig. 4; Table 1).
The average total GAG content of the DiD/ferucarbotran-
labeled pellets was 17.53 (SD 2.91). The relative GAG
content was 0.75 (SD 0.12; Fig. 5). Compared to the
control, DiD/ferucarbotran-labeled hMSC exhibited a
significant inhibition in GAG production (pG0.05).
Discussion
Our study demonstrates that hMSCs can be effectively
labeled by simple incubation with DiD and DiD/ferucarbo-
tran for depiction with OI and MR, without impairing the
cells viability or proliferation. However, while histopatho-
logical evaluation of both unlabeled and labeled cells
demonstrated differentiation into chondrocytes of similar
morphology, labeled cells exhibited significantly less GAG
production. Thus, our data suggest that the applied fluo-
rescent and iron oxide contrast agent label do not interfere
with morphological cell characteristics but may impair cell
function.
Our data are in accordance with studies by Bulte and
colleagues and Henning and colleagues, who recently
described a dose-dependent inhibition of chondrogenesis
with the SPIO based iron oxide labels ferumoxides and
ferucarbotran [3, 4].
Fig. 4. Alcian blue stains of chondrogenic pellets: 1a unlabeled control, 1b DiD labeled, and 1c DiD/ferucarbotran labeled.
1a–c Stained positive (blue stain of the intracellular and extracellular matrix). Safranin-O stains of chondrogenic pellets: 2a
unlabeled control, 2b DiD labeled, and 2c DiD/ferucarbotran labeled. Chondrocytes are visible in all samples with the
morphology of 2b and 2c similar to control. Iron can be visualized in 1c and 2c.
Fig. 5. Average total and relative GAG content of exoge-
nously labeled chondrogenic pellets and controls: Data are
displayed as means of triplicate samples with standard
deviation.
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labeling neurons with Gd-based contrast agents [7], a
diminished self-repair of mesenchymal stem cells after
ferumoxides labeling [8] and a decreased function of natural
killer cells after labeling with FeCl3 [9].
On the other hand, these same cells need iron for their
metabolism and normal development [10, 11]. Iron has a
fundamental role in many metabolic processes, including
electron transport, deoxyribonucleotide synthesis, oxygen
transport, and many essential redox reactions involving
hemoproteins [10]. Iron oxide nanoparticles are in fact
appealing as contrast agents for cell labeling since two
preparations are already FDA-approved (ferumoxides and
ferumoxytol) and since their cellular uptake and intracellular
metabolism have been extensively investigated in patients
[12–14]. Likewise, labeling with fluorochromes has been
reported to interfere with cell functions. For example, the
fluorochrome calcein acetomethylester impaired the migra-
tion capacity of monocytes [15, 16]. Conversely, other
authors reported an unimpaired function of DiD-labeled
natural killer cells [17].
A major challenge of cellular imaging is to develop
optimized cell-labeling techniques, which provide a com-
promise between the minimal possible concentration for
sensitive cell detection, and maximal possible concen-
tration that does not impair cell function. Our data showed
significantly less impairment in GAG production for
chondrocytes labeled with DiD/ferucarbotran as opposed
to cells labeled with DiD alone. A possible explanation
for this observation may be a decreased uptake of DiD
after prelabeling with ferucarbotran. These data support
the theory of Bulte et al. that inhibition of chondro-
genesis by contrast agent labeling is dose dependent [3].
In addition, DiD integrates into the cell membrane and
may interfere with the cell–cell contact needed for
chondrogenesis [18].
We recognize several limitations to our study: Firstly, we
examined stem cell differentiation in vitro;d i f f e r e n t i a t i o n
processes are more complex in vivo a n dh a v et ob er e -
evaluated in this context. Secondly, we focused our inves-
tigations on the fluorescent dye DiD and the iron oxide
contrast agent ferucarbotran. Further studies have to inves-
tigate the effect of other fluorescent dyes and other MR
contrast agents on stem cell differentiation. Lastly, we
examined human mesenchymal stem cells; other stem cell
types may be more or less sensitive to contrast agent labeling.
Conclusions
DiD/ferucarbotran labeling is appealing for monitoring stem
cell transplants with “multimodality” imaging in order to
integrate the high sensitivity provided by OI with the
anatomical details provided by MR. Our data demonstrate that
labeling with DiD and DiD/ferucarbotran enabled noninvasive
long-term visualization of MSC and their progenies with OI
and MRI but lead to inhibition of GAG production of labeled
cells compared to controls. Thus, careful optimizations of
labeling techniques are necessary in order to avoid interference
with the cellular process that should be monitored.
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